390 related articles for article (PubMed ID: 10791201)
21. [The value of CEA immunoscintigraphy for diagnosis of colorectal cancer and its metastases: results of a prospective study].
Imdahl A; Bräutigam P; Hauenstein KH; Eggstein S; Waninger J; Farthmann EH
Zentralbl Chir; 1994; 119(1):17-22. PubMed ID: 8147155
[TBL] [Abstract][Full Text] [Related]
22. [Comparative study of CEA antibody scan and computed tomography scan in the follow-up of patients with colorectal cancer].
García Vicente A; Soriano Castrejón A; González R; Rodado Marina S; Poblete García VM
Rev Esp Med Nucl; 2002; 21(5):349-55. PubMed ID: 12236910
[TBL] [Abstract][Full Text] [Related]
23. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
Doerr RJ; Herrera L; Abdel-Nabi H
Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
[TBL] [Abstract][Full Text] [Related]
24. Immunoscintigraphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58.
Yao YF; Yang Z; Li ZF; Gu J
World J Gastroenterol; 2007 Mar; 13(12):1841-6. PubMed ID: 17465478
[TBL] [Abstract][Full Text] [Related]
25. [Successful immunoscintigraphic tumor detection with technetium 99m marked monoclonal anti-CEA antibodies].
Baum RP; Lorenz M; Hertel A; Baew-Christow T; Schwarz A; Hör G
Onkologie; 1989 Aug; 12 Suppl 1():26-9. PubMed ID: 2685692
[TBL] [Abstract][Full Text] [Related]
26. Immunoscintigraphy with 99Tcm-labelled monoclonal anti-CEA BW 431/26 antibodies in patients with suspected recurrent and metastatic colorectal carcinoma: two-year follow-up.
Lacić M; Bokulić T; Lukac J; Baum RP; Kusić Z
Nucl Med Commun; 1999 Sep; 20(9):859-65. PubMed ID: 10533193
[TBL] [Abstract][Full Text] [Related]
27. Semiquantitative SPECT tumor uptake of technetium-99m-labeled anti-CEA monoclonal antibody in colorectal tumor.
Oriuchi N; Endo K; Watanabe N; Sugiyama S; Asao T; Takenoshita S; Nagamachi Y; Baum RP
J Nucl Med; 1995 Apr; 36(4):679-83. PubMed ID: 7699464
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
29. Anticarcinoembryonic antigen immunoscintigraphy with a 99mTc-Fab' fragment (Immu 4) in primary and recurrent colorectal cancer. A prospective study.
Lechner P; Lind P; Binter G; Cesnik H
Dis Colon Rectum; 1993 Oct; 36(10):930-5. PubMed ID: 8404384
[TBL] [Abstract][Full Text] [Related]
30. [Immunoscintigraphy in colorectal cancers from the viewpoint of the gastroenterologist].
Dippold WG; Wittig BM; Hach A; Hahn K; Meyer zum Büschenfelde KH
Z Gastroenterol; 1990 Dec; 28(12):673-7. PubMed ID: 2087823
[TBL] [Abstract][Full Text] [Related]
31. [Immunoscintigraphy of a colorectal tumor recurrence using a 99mTc-labeled anti-CEA-antibody].
Rilinger N; Niemann H; Halbfass HJ
Rontgenpraxis; 1989 Jul; 42(7):245-7. PubMed ID: 2756446
[No Abstract] [Full Text] [Related]
32. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group.
Moffat FL; Pinsky CM; Hammershaimb L; Petrelli NJ; Patt YZ; Whaley FS; Goldenberg DM
J Clin Oncol; 1996 Aug; 14(8):2295-305. PubMed ID: 8708720
[TBL] [Abstract][Full Text] [Related]
34. [Radioimmunoscintigraphy of colorectal tumors with 99m-Tc marked CEA antibodies. Indications and clinical value].
Barzen G; Martini I; Schulz W; Löhde E; Böse-Landgraf J; Richter W; Langer M; Felix R
Med Klin (Munich); 1992 Aug; 87(8):395-402. PubMed ID: 1406470
[TBL] [Abstract][Full Text] [Related]
35. [The clinical relevance of anti-CEA immunoscintigraphy with the 99mTc-labelled monoclonal antibody BW 431/26. A critical assessment after 119 studies].
Hach A; Wittig B; Piepenburg R; Steinert H; Lahmann C; Dippold W; Hahn K
Rofo; 1992 Jul; 157(1):3-10. PubMed ID: 1638001
[TBL] [Abstract][Full Text] [Related]
36. A freeze dried kit formulation for the preparation of 99mTc-EHDP-MoAb-IOR CEA1 complex.
Ferro-Flores G; Lezama-Carrasco J
Nucl Med Biol; 1994 Oct; 21(7):1013-6. PubMed ID: 9234358
[TBL] [Abstract][Full Text] [Related]
37. [Radioimmunodetection of colorectal cancer, using anti-CEA monoclonal antibody CEA102: experience of 20 cases].
Murakami K; Watanabe T; Tadokoro M; Sakamoto J; Murayama H; Wada K; Sakuma S; Takagi H
Nihon Geka Gakkai Zasshi; 1993 Feb; 94(2):119-27. PubMed ID: 8464409
[TBL] [Abstract][Full Text] [Related]
38. Detection of pelvic recurrence of colorectal carcinoma: prospective, blinded comparison of Tc-99m-IMMU-4 monoclonal antibody scanning and CT.
Stomper PC; D'Souza DJ; Bakshi SP; Rodriguez-Bigas M; Burke PA; Petrelli NJ
Radiology; 1995 Dec; 197(3):688-92. PubMed ID: 7480740
[TBL] [Abstract][Full Text] [Related]
39. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.
Hertel A; Baum RP; Lorenz M; Baew-Christow T; Encke A; Hör G
Br J Cancer Suppl; 1990 Jul; 10():34-6. PubMed ID: 2166552
[TBL] [Abstract][Full Text] [Related]
40. Effect of radioimmunoscintigraphy on the management of recurrent colorectal cancer.
Lunniss PJ; Skinner S; Britton KE; Granowska M; Morris G; Northover JM
Br J Surg; 1999 Feb; 86(2):244-9. PubMed ID: 10100796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
